Skip to main content

Table 4 Viruses used in ATAP

From: Oncolytic viruses for cancer immunotherapy

 

Serotype

Main target receptor

Tumor specificity

Arming

Ad5-D24-GMCSF [92]

5

Coxsackie virus and adenovirus receptor

24 bp deletion in E1A1)

GMCSF

Ad5-RGD-D24 [103]

5

Alpha-v-beta integrins

24 bp deletion in E1A1)

No

Ad5-RGD-D24-GMCSF [103]

5

Alpha-v-beta integrins

24 bp deletion in E1A1)

GMCSF

ICOVIR-7 [104]

5

Alpha-v-beta integrins

E2F1 promoter and 24 bp deletion in E1A1)

No

Ad5/3-Cox2L-D24 [73]

5

Desmoglein-2

Cox2L promoter and 24 bp deletion in E1A1)

No

Ad5/3-D24-GMCSF [88]*

5

Desmoglein-2

24 bp deletion in E1A1)

GMCSF

Ad5/3-hTERT-hCD40L [73]

5

Desmoglein-2

hTERT promoter2)

CD40L

Ad5/3-E2F1-D24-GMCSF [105]

5

Desmoglein-2

E2F1 promoter and 24 bp deletion in E1A 1)

GMCSF

Ad5/3-D24-hNIS [80]

5

Desmoglein-2

24 bp deletion in E1A1)

hNIS

Ad3-hTERT-E1A [64]

3

Desmoglein-2

hTERT promoter2)

No

  1. *Ad5/3-D24-GMCSF, also known as CGTG-102, and later renamed ONCOS-102, has been subsequently used in several phase 1 and phase 2 clinical trials (www.targovax.com)
  2. 1)Replication in cells with a deficient Rb/p16 pathway (a hallmark of cancer)
  3. 2)Replication in cells with active telomerase (a hallmark of cancer)